43 results about "Targeting chemotherapy" patented technology

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing HER2-neu and / or EGFR expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable sensitivity of a patient's tumor to treatment with receptor tyrosine kinase targeted chemotherapy by examination of the amount of HER2-neu and / or EGFR mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs EGFR and HER2-neu and methods comprising their use for detecting levels of EGFR and HER2-neu mRNA, respectively.

Disclosed herein are non-platinum-based (NPB) anti-cancer compounds useful for targeted chemotherapy, e.g., to generate anti-cancer effects for the treatment of cancer and other disorders while having no or minimal toxicity. The compounds N have the general formula I: (I) wherein A represents an aromatic core; at least one of Ra and Rb is an electron transfer promoter as defined herein, e.g., NH2; and at least one of Rc is a leaving group as defined herein, e.g., halogen; and the remainder of the molecule is as defined herein. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the anti-cancer compounds are also disclosed.

The invention discloses an esophagus cancer chemotherapy device. The device comprises an esophagus inserting structure, a rubber probing tube with the top end provided with a connecting part, an extruding tube in threaded connection with the connecting part, a minitype hemi-spherical emulsion bag, an esophagus cancer locating structure and a cancer cell target chemotherapy structure, a hollow structure inside the minitype hemi-spherical emulsion bag is communicated with the inside of the rubber probing tube, and the hollow structure of the minitype hemi-spherical emulsion bag and the inside ofthe rubber probing tube are filled with minitype filling blocks; the external diameter of the extruding tube is less than the inner diameter of the rubber probing tube, and the inner diameter of theextruding pipe is less than the width of each minitype filling block, and the esophagus cancer locating structure comprises a drawstring ring and a cancer cell locator; the cancer cell target chemotherapy structure comprises medicine loading cotton filled with the inner wall of the minitype hemi-spherical emulsion bag, a drawstring ring and a digging rope, and a puller is arranged at the other endof the digging rope. The esophagus cancer chemotherapy device effectively reduces the chemotherapy difficulty and greatly promotes the accuracy, effectiveness and security of the chemotherapy.

The present invention relates to a magnetic nanoparticle for tumor therapy, comprising: a magnetic core; a shell encapsulating a surface of the magnetic core, wherein the shell is made of a polymer with carboxylic groups; a poly-nucleotide chain connected to a surface of the shell; an anti-tumor drug connected to the poly-nucleotide chain, wherein the anti-tumor drug comprises at least one functional group, and each of the functional group is independently a pyrimidine group or a purine group; and an antibody connected to the shell, wherein the antibody identifies a target tumor. In addition, the present invention further provides a method for manufacturing the magnetic nanoparticles for tumor therapy and a pharmaceutical composition containing the magnetic nanoparticles. Accordingly, the magnetic nanoparticle for tumor therapy of the present invention can achieve effective treatment of tumor by synergistic effects between hyperthermia and targeted chemotherapy.

The present invention relates to a targeted photothermal therapy combined with immunotherapy anti-tumor compound preparation and its preparation method and application, which consists of Cypate liposome, Adriamycin-Bovine Serum Albumin (ADM-BSA) and hyaluronic acid-Adriamycin element (HA‑ADM) composition. The chemical stability of Cypate entrapped in liposomes is significantly better than that of free Cypate, and the in vitro heating effect is stronger, and it has good tumor targeting and photothermal therapy effects. Cypate liposome has good targeting and has strong photothermal therapy effect. Combining ADM‑BSA and HA‑ADM constitutes a dual-targeted hyaluronic acid‑hapten immune preparation for immunotherapy and active targeted chemotherapy. The treatment effect of residual and metastatic tumor cells is good, which can avoid the defects of each treatment and achieve the purpose of synergistic treatment.

Provided herein are methods for treating cancer comprising administering a metabolically targeted chemo-immunotherapy regimen. In one embodiment, a metabolically targeted chemo-immunotherapy regimen may comprise the step of administering a therapeutically effective dose of one or more immunizing agents (e.g., therapeutic antibodies) in a subject with cancer to stimulate immune responding; reducing blood glucose levels in the patient; and administering a therapeutically effective dose of one or more chemotherapeutic agents. The methods described herein are useful in the treatment of any type of cancer, particularly malignant and metastatic advanced cancers.

The invention provides a probe assembly, a gene capturing chip, a kit and application. The assembly at least comprises a probe specifically combined to a target gene under the strict conditions. A special capturing probe is designed for a targeted chemotherapy medicine related gene on the basis of the DNA next generation sequencing method, a plurality of target gene segments are obtained at a time through a small number of samples, high-depth sequencing is achieved through a high-flux sequencing platform, the genetic polymorphism of chemotherapy medicine and various deviant forms such as point mutation, insertion / deletion and DNA copy number alteration in targeted medicine related gene can be detected at a time in parallel, and therefore all target gene mutations related to targeted chemotherapy treatment are detected at a time. Thus, options are provided for clinical doctors in a real sense, a more suitable treatment scheme can be obtained only through single detection, and treatment cost and time are saved for patients to a larger extent.

Disclosed are compound for targeting chemotherapeutic agents to mammalian mitochondria. Also disclosed are monoamine oxidase-specific compositions, and methods of using them for the selective therapy of mammalian cancers, and in particular, in the treatment of human gliomas. Also disclosed are methods employing the novel targeted chemotherapeutics with one or more conventional anti-cancer therapies, including, for example, radiotherapy, or multi-drug regimens.